# Standard Clinical Scenario Header
scenario:
  id: "primary-care-treatment-diabetes-001"
  title: "Type 2 Diabetes with ASCVD - Cardioprotective Therapy Initiation"
  domain: "primary-care"
  category: "treatment-recommendation"
  condition: "diabetes"
  version: "1.0"
  created: "2025-11-08"
  author: "Clinical BDD Creator"
  guidelines:
    - name: "ADA 2025 Standards of Care in Diabetes"
      section: "Section 9 - Pharmacologic Approaches to Glycemic Treatment"
      url: "https://diabetesjournals.org/care/issue/48/Supplement_1"
    - name: "ASCVD Risk Management in Diabetes"
      reference: "Cardiovascular risk reduction strategies"

# Clinical Context
clinical:
  patient:
    demographics:
      age: 65
      gender: "male"
      ethnicity: "not specified"
    
    presentation:
      chief_complaint: "Undiagnosed Type 2 Diabetes"
      discovery_method: "elevated HbA1c screening"
      symptoms: "likely asymptomatic or mild hyperglycemia symptoms"
  
  diagnosis:
    primary: "Type 2 Diabetes Mellitus"
    status: "undiagnosed until now"
    severity: "inadequately controlled"
    evidence:
      - lab: "HbA1c"
        value: 8.5
        unit: "percent"
        interpretation: "above target of <7%"
  
  comorbidities:
    - name: "Atherosclerotic Cardiovascular Disease (ASCVD)"
      type: "established ASCVD"
      evidence: "history of myocardial infarction"
      status: "active"
      risk_level: "high cardiovascular risk"
      impact: "mandates cardioprotective diabetes therapy"
  
  vitals:
    blood_pressure: "to be monitored"
    weight: "to be monitored"
    note: "cardiovascular monitoring required"
  
  labs:
    hba1c:
      value: 8.5
      unit: "percent"
      target: "< 7%"
      status: "elevated"
    
    egfr: "adequate for SGLT2i and GLP-1 RA"
    renal_status: "monitor for cardiorenal protection"
    
    note: "confirm T2DM diagnosis and monitor eGFR"
  
  medications:
    current: "likely none for diabetes (newly diagnosed)"
    allergies: []
  
  contraindications:
    sglt2i:
      - condition: "eGFR < 30 mL/min/1.73mÂ²"
        status: "not present"
      - condition: "history of euglycemic ketoacidosis"
        status: "not present"

# Expected Clinical Actions
expectations:
  recommendations:
    - type: "medication"
      drug_class: "SGLT2 inhibitor"
      rationale: "First-line for diabetes with ASCVD - proven cardiovascular benefit"
      options:
        - name: "empagliflozin"
        - name: "dapagliflozin"
        - name: "canagliflozin"
      considerations: "Cardiorenal protection regardless of glycemic control"
      evidence: "EMPA-REG, CANVAS, DECLARE-TIMI trials"
    
    - type: "medication"
      drug_class: "GLP-1 receptor agonist"
      rationale: "First-line for diabetes with ASCVD - proven cardiovascular benefit"
      options:
        - name: "liraglutide"
        - name: "semaglutide"
        - name: "dulaglutide"
      considerations: "Alternative or addition to SGLT2i for ASCVD protection"
      evidence: "LEADER, SUSTAIN-6, REWIND trials"
    
    - type: "medication"
      drug_class: "Metformin"
      status: "consider as adjunct"
      rationale: "Traditional first-line agent, may be used alongside SGLT2i/GLP-1 RA"
      note: "No longer sole first-line in high-risk ASCVD patients per ADA 2025"
  
  treatment_strategy:
    approach: "Escalate to dual therapy with cardioprotective agents"
    priority: "SGLT2 inhibitor or GLP-1 RA first-line for ASCVD"
    rationale: "High HbA1c (8.5%) + established ASCVD mandates aggressive cardioprotective therapy"
    targets:
      hba1c: "< 7%"
      cardiovascular_risk: "reduction through evidence-based agents"
  
  monitoring:
    - type: "labs"
      tests: ["HbA1c"]
      frequency: "every 3 months"
      target: "< 7%"
      rationale: "Monitor glycemic control response to therapy"
    
    - type: "labs"
      tests: ["eGFR", "creatinine"]
      frequency: "baseline and periodic"
      rationale: "Monitor renal function for SGLT2i safety and cardiorenal protection"
    
    - type: "labs"
      tests: ["lipid panel"]
      frequency: "periodic"
      rationale: "Comprehensive cardiovascular risk management"
    
    - type: "clinical"
      parameters: ["blood pressure", "weight"]
      frequency: "each visit"
      rationale: "Monitor cardiovascular status and treatment effects"
    
    - type: "cardiovascular"
      assessments: ["ASCVD status", "cardiac symptoms"]
      frequency: "ongoing"
      rationale: "Monitor for cardiovascular events and therapy efficacy"
  
  education:
    topics:
      - "Type 2 diabetes diagnosis and implications"
      - "Cardiovascular risk and importance of cardioprotective therapy"
      - "Medication adherence for SGLT2i/GLP-1 RA"
      - "Blood glucose monitoring if initiated"
      - "Lifestyle modifications (diet, exercise, weight management)"
      - "ASCVD secondary prevention strategies"
      - "Recognition of hyperglycemia and hypoglycemia symptoms"
      - "When to seek medical attention"

# Test Metadata
testing:
  complexity: "advanced"
  fidelity: "medium"
  priority: "P2"
  tags:
    - "type-2-diabetes"
    - "ASCVD"
    - "cardioprotective-therapy"
    - "SGLT2-inhibitor"
    - "GLP-1-agonist"
    - "new-diagnosis"
    - "high-risk"
  
  clinical_decision_points:
    - "Recognition of high cardiovascular risk requiring cardioprotective agents"
    - "Preference for SGLT2i or GLP-1 RA over traditional metformin monotherapy"
    - "Dual therapy approach for high HbA1c and ASCVD"
    - "Monitoring for both glycemic control and cardiovascular outcomes"
  
  edge_cases:
    - "Newly diagnosed diabetes with established ASCVD"
    - "High HbA1c (8.5%) requiring aggressive management"
    - "Paradigm shift from metformin-first to cardioprotective agents first"
    - "Monitoring for cardiorenal protection beyond glycemic control"

# Source Mapping
source:
  original_file: "JohnSmith_Diabetes_ASCVD"
  original_location: "examples/bdd-tests/unsorted/"
  original_case_id: "JohnSmith_Diabetes_ASCVD"
  original_bundle_id: "Bundle-JohnSmith-Diabetes-ASCVD"
  migration_date: "2025-11-08"
  notes: "Converted from reference-based format to standardized format emphasizing cardioprotective therapy per ADA 2025 guidelines"
